With its promises of improved diagnostic and treatment outcomes for arthritis, breast cancer, and other conditions, genetic testing is on a trajectory to becoming a mainstay of the healthcare system. But the field is poorly regulated, prompting calls for more government oversight to help ensure patient privacy and testing accuracy, according to an article scheduled for the July 7 issue of Chemical & Engineering News.
In the article, C&EN Associate Editor Britt E. Erickson points out that genetic tests are now available for some 1,200 different clinical conditions and more tests are in the development pipeline.
With more and more genetic information published on the Internet and the growth of direct-to-consumer genetic testing, there's an urgent need for more government action to help maintain patient privacy while ensuring that test claims are accurate and clinically useful, the article notes.
Changes are already in the works. The Food and Drug Administration (FDA) indicates that it plans to expand oversight of genetic testing in the future. "As the FDA moves to regulate some aspects of this testing area, congressional action will likely be needed to help manage the growth of this emerging health care issue," the article states. At least two states, New York and California, already require genetic-testing companies to prove the validity of their tests.
Source: ACS
Related stories:
Statin does not appear helpful for children with learning disabilities caused by genetic disorder
Use of simvastatin by children with neurofibromatosis type 1 (NF1), a genetic disorder that can cause learning disabilities, did not result in improved cognitive function, according to a study in the July 16 issue of
JAMA.
Gold, DNA Combination May Lead To Nano-Sensor
The ability to use genetic material to assemble nanoscopic particles of gold could be an important step toward creating tiny “spies” that will be able to infiltrate individual cells and report back in real time on the cell’s inner workings.
Researchers find human virus in chimpanzees
After studying chimpanzees in the wilds of Tanzania's Mahale Mountains National Park for the past year as part of a National Science Foundation (NSF) grant, Virginia Tech researcher Dr. Taranjit Kaur and her team have produced powerful scientific evidence that chimpanzees are becoming sick from viral infectious diseases they have likely contracted from humans.
Determining genetic signature of lung tumors can help guide treatment
The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning. The report appears in the May 20
Journal of Clinical Oncology.
Vaccine triggers immune response, prevents Alzheimer's
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer’s disease-like pathology in mice without causing inflammation or significant side effects.
Gene therapy improves vision in patients with congenital retinal disease
In a clinical trial at The Children’s Hospital of Philadelphia, researchers from The University of Pennsylvania have used gene therapy to safely restore vision in three young adults with a rare form of congenital blindness. Although the patients have not achieved normal eyesight, the preliminary results set the stage for further studies of an innovative treatment for this and possibly other retinal diseases.
At Home Genomic Tests for Disease Risk Premature
The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
Applying genomic medicine into clinical practice for chronic diseases still in the early stages
A large gap exists between what knowledge is available about genomic medicine and incorporating it into clinical practice for assessing the risk of and treating common chronic diseases, such as cardiovascular disease, diabetes mellitus, and cancer, according to a systematic review in the March 19 issue of JAMA, a theme issue on
Genetics and Genomics.